Liver study tests hepatitis b drug safety in impaired patients
NCT ID NCT07342868
First seen Jan 19, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage study looks at how the body handles a single dose of the experimental hepatitis B drug pevifoscorvir sodium in people with moderate liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver problems change how the drug works, which helps doctors decide on safe dosing in future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPAITITIS B INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.